Claims for Patent: 6,079,415

Summary for Patent: 6,079,415

Title:	Process for evaluating the damage induced in skin by UV-A radiation
Abstract:	A process for evaluating the type A ultraviolet radiation induced damage to the skin and/or the dermis. The invention also relates to a method of evaluating substances capable of modulating the damage induced in the skin and/or dermis by type A ultraviolet radiation.
Inventor(s):	Bernerd; Fran.cedilla.oise (Paris, FR), Asselineau; Daniel (Antony, FR)
Assignee:	Societe L\'Oreal S.A. (Paris, FR)
Application Number:	08/997,256
Patent Claims:	1. A process for evaluating the damage induced in skin by type A ultraviolet radiation, said process comprising: (A) obtaining an in vitro skin equivalent; (B) subjecting said skin equivalent to at least a type A ultraviolet radiation for a sufficient time to induce the variation of a marker specific for the damage induced in the skin by type A ultraviolet radiation; (C) measuring the variation of said marker; and (D) evaluating the results of the measurement of the variation in the marker relative to a control as a means of determining the amount of change induced by type A ultraviolet radiation. 2. The process as defined by claim 1, wherein the variation of the marker is measured for the damage induced by type A ultraviolet radiation. 3. The process as defined by claim 1, wherein the skin equivalent is an epidermis and a living dermis equivalent. 4. The process as defined by claim 1, wherein the type A ultraviolet radiation has a wavelength ranging from of at least 320 nm to 400 nm. 5. The process as defined by claim 1, wherein the time for type A ultraviolet radiation ranges from 1 minute to a few hours. 6. The process as defined by claim 5, wherein the time for the type A ultraviolet radiation ranges from 5 minutes to 120 minutes. 7. The process as defined by claim 1, wherein the marker specific for the damage induced by the type A ultraviolet radiation is selected from the group consisting of: a cell; a cell population; a nucleic acid; a protein; a group of proteins, bound or otherwise; an ion; a cellular organelle; a lipid; and a polysaccharide. 8. The process as defined by claim 1, wherein the marker specific for the damage induced by the type A ultraviolet radiation is the quantity of type I collagenase produced by the fibroblasts. 9. The process as defined by claim 1, wherein the marker specific for the damage induced by type A ultraviolet radiation is the number of fibroblasts in the dermis. 10. The process as defined by claim 1, wherein the marker specific for the damage induced by the type A ultraviolet radiation is the level of recolonization of the dermis by the subjacent fibroblasts. 11. The process as defined by claim 1, wherein the control is the same assay carried out under the same conditions, but in the absence of any irradiation or in the presence of irradiation with radiation having different characteristics. 12. The process as defined by claim 11, wherein the control is a skin equivalent which has not been subjected to any irradiation. 13. A process for evaluating the ability of a substance to modulate damage induced in the skin by type A ultraviolet radiation, said process comprising: (A) obtaining an in vitro skin equivalent; (B) subjecting said skin equivalent to at least a type A ultraviolet radiation for a sufficient time to induce variation of a marker specific for the damage induced in the skin by type A ultraviolet radiation; (C) measuring the variation of said marker; (D) evaluating the results of the measurement of the variation in the marker relative to a control; (E) treating the skin equivalent with a substance which is to be evaluated for its ability to modulate damage to the skin caused by type A ultraviolet radiation for a sufficient time, before or after irradiating said skin equivalent; and (F) comparing the variation of the expression of said marker in said irradiated skin equivalent to the results of step D to evaluate the ability of said substance on the modulation of the damage to skin caused by type A ultraviolet radiation. 14. The process as defined by claim 13, wherein the control is a skin equivalent previously treated with a different quantity of the substance to be tested or of a skin equivalent not treated with the substance to be tested. 15. The process as defined by claim 13 wherein the control is a skin equivalent not treated with the substance to be tested. 16. The process as defined by claim 13, wherein the skin equivalent is treated for a time ranging from a few seconds to several days. 17. The process as defined by claim 13, wherein the skin equivalent is treated for a time ranging from 5 minutes to 15 days.

Details for Patent 6,079,415

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2016-12-24